Cytocare Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 17 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.00 M
as on 16-11-2024
- Revenue 68.22%
(FY 2023)
- Profit -764.59%
(FY 2023)
- Ebitda -396.35%
(FY 2023)
- Net Worth -32.46%
(FY 2023)
- Total Assets 7.82%
(FY 2023)
About Cytocare Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹2.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Partha Ghosh and Gopa Ghosh serve as directors at the Company.
- CIN/LLPIN
U24232WB2007PTC117462
- Company No.
117462
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jul 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cytocare Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Partha Ghosh  | Director | 25-Jul-2007 | Current |
| Gopa Ghosh | Director | 25-Jul-2007 | Current |
Financial Performance of Cytocare Formulations.
Cytocare Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.22% increase. The company also saw a substantial fall in profitability, with a 764.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 32.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cytocare Formulations?
In 2023, Cytocare Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Creation Medicare Private LimitedActive 17 years 22 daysPartha Ghosh and Gopa Ghosh are mutual person
- Genx Confectionaries Private LimitedActive 11 years 7 months
Partha Ghosh and Gopa Ghosh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 15 Feb 2012 | ₹2.00 M | Satisfied |
How Many Employees Work at Cytocare Formulations?
Unlock and access historical data on people associated with Cytocare Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cytocare Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytocare Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
